Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 579-587

  Shu, Haihua ^a,b   Hayashida, Masakazu ^b,c   Arita, Hideko ^b,d   Huang, Wenqi ^a   Zhang, Hui ^a   An, Ke ^a   Wu, Guiyun ^a   Hanaoka, Kazuo ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d JR Tokyo General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOCINNAMOX; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NORBINALTORPHIMINE; PENTAZOCINE; PLACEBO; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; EXPERIMENTAL TEST; HOT PLATE TEST; LOW DRUG DOSE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; TAIL FLICK TEST; TAIL PRESSURE TEST; WRITHING TEST;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED C57BL; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PENTAZOCINE; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 79960548478     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179879     Document Type: Article

References (37)

1. Bidlack JM, McLaughlin JP, and Wentland MP (2000) Partial opioids. Medications for the treatment of pain and drug abuse. Ann NY Acad Sci 909:1-11.
2. Butelman ER, Negus SS, Lewis JW, and Woods JH (1996) Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys. Psychopharmacology 123:320-324. (Pubitemid 26076654)
3. Cervero F and Laird JM (2004) Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol 61:45-54. (Pubitemid 39287769)
4. Chiba S, Hayashida M, Yoshikawa M, Shu H, Nishiyama T, and Yamada Y (2009) Inhibitory effect of low-dose pentazocine on the development of antinociceptive tolerance to morphine. J Anesth 23:99-107.
5. Chien CC and Pasternak GW (1995) (-)-Pentazocine analgesia in mice: interactions with a sigma receptor system. Eur J Pharmacol 294:303-308.
6. Delaney KM, Rourke JD, and Shaw JS (1986) Sensitivity of antinociceptive tests to opioid agonists and partial agonists. NIDA Res Monogr 75:438-441.
7. Endoh T, Matsuura H, Tanaka C, and Nagase H (1992) Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42.
8. Fudala PJ and Johnson RE (2006) Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 83:S40-S47.
9. Fürst S (1991) Pharmacological interaction of opiates with various classes of centrally acting dopaminergic drugs. Drug Metab Drug Interact 9:77-102.
10. Fürst S and Hosztafi S (2008) The chemical and pharmacological importance of morphine analogues. Acta Physiol Hung 95:3-44.
11. Gutstein HB and Akil H (2006) Opioid analgesics, in Goodman and Gilman's: the pharmacological basis of therapeutics (Brunton LL, Lazo JS, and Parker KL, eds) pp 547-590, McGraw-Hill/Hardman, New York.
12. Hayes AG and Tyers MB (1983) Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol 79:731-736.
13. Hoskin PJ and Hanks GW (1991) Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 41:326-344. (Pubitemid 21920731)
14. Kinouchi K, Fukumitsu K, Takezawa J, Maeda S, Enomoto H, Kakuhari J, Yoshiya I, and Inoki R (1986) Stereospecific effects of D- and L-pentazocine on contractions of the mouse vas deferens. Life Sci 39:127-133. (Pubitemid 16057800)
15. Kurihara T, Nonaka T, and Tanabe T (2003) Acetic acid conditioning stimulus induces long-lasting antinociception of somatic inflammatory pain. Pharmacol Biochem Behav 74:841-849. (Pubitemid 36351649)
16. Lutfy K and Cowan A (2004) Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2:395-402. (Pubitemid 39276631)
17. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, et al. (2003) Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337. (Pubitemid 37444610)
18. Meng ID, Johansen JP, Harasawa I, and Fields HL (2005) Kappa opioids inhibit physiologically identified medullary pain modulating neurons and reduce morphine antinociception. J Neurophysiol 93:1138-1144. (Pubitemid 40283705)
19. Moynihan H, Jales AR, Greedy BM, Rennison D, Broadbear JH, Purington L, Traynor JR, Woods JH, Lewis JW, and Husbands SM (2009) 14-β-O- cinnamoylnaltrexone and related dihydrocodeinones are μ opioid receptor partial agonists with predominant antagonist activity. J Med Chem 52:1553-1557.
20. Pan ZZ (1998) μ-Opposing actions of κ-opioid receptor. Trends Pharmacol Sci 19:94-98.
21. 3H]DAMGO binding in rats. Eur J Pharmacol 337:27-34.
22. Preston KL and Bigelow GE (1993) Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264:813-823. (Pubitemid 24283545)
23. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, and Reisine T (1994) Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol 45:330-334.
24. Ren Y, Zhang L, Lu Y, Yang H, and Westlund KN (2009) Central lateral thalamic neurons receive noxious visceral mechanical and chemical input in rats. J Neurophysiol 102:244-258.
25. Schmauss C (1987) Spinal κ-opioid receptor-mediated antinociception is stimulusspecific. Eur J Pharmacol 137:197-205.
26. Schmauss C, Yaksh TL, Shimohigashi Y, Harty G, Jensen T, and Rodbard D (1983) Differential association of spinal μ, δ, and κ opioid receptors with cutaneous thermal and visceral chemical nociceptive stimuli in the rat. Life Sci 33:653-656.
27. Shaw JS, Rourke JD, and Burns KM (1988) Differential sensitivity of antinociceptive tests to opioid agonists and partial agonists. Br J Pharmacol 95:578-584.
28. Shu H, Arita H, Hayashida M, Chiba S, Sekiyama H, and Hanaoka K (2006a) Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappaopioid receptors. J Ethnopharmacol 106:263-271. (Pubitemid 43766191)
29. Shu H, Arita H, Hayashida M, Sekiyama H, and Hanaoka K (2006b) Effects of processed Aconiti tuber and its ingredient alkaloids on the development of antinociceptive tolerance to morphine. J Ethnopharmacol 103:398-405. (Pubitemid 43143376)
30. Shu H, Hayashida M, Arita H, Huang W, Xiao L, Chiba S, Sekiyama H, and Hanaoka K (2008) High doses of processed Aconiti tuber inhibit the acute but potentiate the chronic antinociception of morphine. J Ethnopharmacol 119:276-283.
31. Shu H, Hayashida M, Chiba S, Sekiyama H, Kitamura T, Yamada Y, Hanaoka K, and Arita H (2007) Inhibitory effect of processed Aconiti tuber on the development of antinociceptive tolerance to morphine: evaluation with a thermal assay. J Ethnopharmacol 113:560-563. (Pubitemid 47361560)
32. Suzuki T, Narita M, Misawa M, and Nagase H (1991) Pentazocine-induced biphasic analgesia in mice. Life Sci 48:1827-1835.
33. Tanimoto S, Nakagawa T, Yamauchi Y, Minami M, and Satoh M (2003) Differential contributions of the basolateral and central nuclei of the amygdala in the negative affective component of chemical somatic and visceral pains in rats. Eur J Neurosci 18:2343-2350. (Pubitemid 38117408)
34. Tyers MB (1980) A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol 69:503-512.
35. Yaksh TL (1997) Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41:94-111.
36. Zacny JP, Hill JL, Black ML, and Sadeghi P (1998) Comparing the subjective, psychomotor and physiological effects of intravenous pentazocine and morphine in normal volunteers. J Pharmacol Exp Ther 286:1197-1207. (Pubitemid 29135530)
37. Zernig G, Burke T, Lewis JW, and Woods JH (1996) Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays. J Pharmacol Exp Ther 279:23-31. (Pubitemid 27166889)